Shanghai Apeptide Co.,Ltd.
Public registration snapshot and company identity context for supplier due diligence.
This snapshot currently shows
- registration status continuation.
- registered region Shanghai, Pudong New Area.
- established on Mar 11, 2010.
- legal representative 马良会.
- source data last refreshed on Mar 13, 2026.
Need a deeper company check?
Move from this public snapshot to a fuller company report when you need more context before payment, contracting, or onboarding.
Fact summary
- English name
- Shanghai Chu Peptide Biotechnology Co., Ltd
- Chinese registered name
- 上海楚肽生物科技有限公司
- USCC / credit code
- 91310115551571133E
- Legal representative
- 马良会
- Established
- Mar 11, 2010
- Region
- Shanghai, Pudong New Area
- Registered capital
- ¥5,000,000 RMB
Company identity mapping
The public page uses the English name "Shanghai Apeptide Co.,Ltd." as a readable label for the Chinese registered entity "上海楚肽生物科技有限公司". The underlying company record is matched to the English company name "Shanghai Chu Peptide Biotechnology Co., Ltd" where available.
English names can be translated, self-reported, or used commercially. Before payment or contract signing, confirm that the English-facing supplier identity matches the Chinese legal entity and unified social credit code.
The registered region shown for this entity is Shanghai, Pudong New Area. Cross-check that region against contracts, invoices, shipping documents, and bank instructions when supplier details are being verified.
What to verify next
Use the facts on this page as a checklist before you rely on supplier identity, payment details, or contracting documents.
- Confirm that the unified social credit code on invoices, contracts, bank details, and supplier documents matches the code shown on this page exactly.
- Treat "Shanghai Apeptide Co.,Ltd." as a readable supplier-facing label, but verify whether it maps cleanly to the company name "Shanghai Chu Peptide Biotechnology Co., Ltd" in contracts, invoices, catalogs, and payment instructions.
- Cross-check the region "Shanghai, Pudong New Area" against shipping documents, onboarding forms, invoices, and beneficiary information to catch location mismatches early.
- If the transaction is sensitive, compare the listed legal representative "马良会" against authorization documents, company chops, and public filing materials where available.
- Review what the registration status "continuation" means for your transaction, especially if you are about to pay, sign a contract, or onboard the supplier.
- If timing matters, re-check the entity close to payment or signature time because the current public snapshot was last refreshed on Mar 13, 2026.
Why these facts matter
This snapshot currently shows the company as "continuation". Because that wording is less clear than a simple active-or-cancelled state, it deserves manual review before money or documents are sent.
This page uses "Shanghai Apeptide Co.,Ltd." as the readable English-facing label, while the company record is tied to "Shanghai Chu Peptide Biotechnology Co., Ltd" and the Chinese entity "上海楚肽生物科技有限公司". That distinction matters when supplier branding differs from the registered legal name.
The available region for this record is Shanghai, Pudong New Area. Use that region as a cross-check against invoices, shipping paperwork, onboarding forms, and beneficiary details.
The listed legal representative is 马良会. This is another identity anchor you can compare with contracts, seals, authorization letters, and public records.
The underlying public registration snapshot was last refreshed on Mar 13, 2026. If your payment or signing decision depends on the latest state, re-check the entity when the transaction window is time-sensitive.
Before payment, compare the registered company identity, credit code, and region against invoices, contracts, banking instructions, and supplier communications.
Important boundary
This page is based on public registration information and internal presentation logic for identity review.
It is designed to support company verification and due-diligence decisions, not to guarantee commercial safety or trustworthiness.
It does not constitute legal advice, legal conclusions, or an accusation about the company.